The Canadian patent 2932428 is valid through 2034 and the Indian patent 289123 is valid through 2028.
The chemical entities are considered useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia, it said.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” said Venkat Jasti, CEO of Suven.
The granted claims of the patents include the class of selective 5-HT 4 and 5-HT 6 compounds respectively and are being developed as therapeutic agents for major depressive disorders, it said.
Suven Life Sciences Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products.
It has four clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and Phase 1 commenced SUVN-911.